[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625051":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":36,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Ronan ABGRAL, Pr","CONTACT","+332 98 22 30 69","ronan.abgral@chu-brest.fr",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Jean-Christophe LECLERE, Dr","+332 98 22 02 91","jean-christophe.leclere@chu-brest.fr",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"CHU Brest","RECRUITING","Brest","29200","France","FR",{"type":27,"coordinates":28},"Point",[29,30],-4.48628,48.39029,{"lat":30,"lon":29},[33],{"name":34,"role":11,"phone":35,"phoneExt":7,"email":17},"Jean-Christophe Leclere, Dr","+33229020291",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100625051",false,"NCT07417605","Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.","POLARIS","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Presenting with head and neck squamous cell carcinoma\n* Completed curative treatment with external radiation therapy\n* Eligible for dynamic LAFOV FDG-PET scan for therapeutic evaluation at 3 months\n* Having given consent for the end-of-treatment consultation\n\nExclusion Criteria:\n\n* Hypersensitivity to 18F-FDG or other excipients contained in the contrast agent\n* Pregnancy or breastfeeding\n* History of treated upper gastrointestinal tract cancer\n* Other histology\n* Incomplete RTE treatment regimen\n* Refusal to participate","ALL","18 Years",{"count":47,"type":48},180,"ESTIMATED","OBSERVATIONAL","This multicenter prospective observational study will evaluate the value of dynamic FDG-PET LAFOV imaging during the initial therapeutic assessment of a head and neck cancer 3 months after completion of curative radiotherapy.",[52],"Head & Neck Squamous Cell Carcinoma",[54,55,56,57],"4D dynamic analysis","post-radical inflammation","squamous cell carcinomas","FDG-PET LAFOV","2026-04-21",{"date":60,"type":61},"2026-04-22","ACTUAL",{"date":63,"type":61},"2026-04-13",{"date":65,"type":48},"2029-06-13",{"name":5,"class":6},1]